How Long Until Mesenteric Fibromatosis Recurs?

Desmoid-type fibromatosis—formerly known as aggressive fibromatosis or desmoid tumor—is a rare, locally invasive, non-metastasizing soft-tissue neoplasm arising from musculoaponeurotic structures. When it originates in the mesentery—the membranous fold of peritoneum that suspends the intestines—the condition is termed mesenteric fibromatosis. Despite its benign histology, this disease exhibits unpredictable clinical behavior and a significant propensity for local recurrence.

Recurrence rates following surgical resection vary widely across studies but consistently remain high. In patients with mesenteric fibromatosis, reported 5-year recurrence rates range from 25% to 70%, depending on surgical margins, tumor size, anatomical location, and molecular profile. Positive or close resection margins (<1 mm) are the strongest modifiable predictor of recurrence; however, achieving wide negative margins is often surgically challenging due to proximity to critical vascular and gastrointestinal structures.

Time to recurrence is highly variable: approximately 60–70% of recurrences occur within the first two years postoperatively, with the median time to recurrence falling between 12 and 18 months. Late recurrences—beyond five years—are documented but uncommon, occurring in fewer than 10% of cases. Importantly, recurrence does not imply malignant transformation; desmoid tumors lack metastatic potential and do not progress to sarcoma.

Given the high recurrence risk, multidisciplinary management is essential. Active surveillance may be appropriate for asymptomatic, stable, or slow-growing lesions. First-line systemic therapy for unresectable, recurrent, or progressive disease includes nonsteroidal anti-inflammatory drugs (e.g., sulindac), antiestrogens (e.g., tamoxifen), or targeted agents such as sorafenib and pazopanib. Surgery remains indicated for symptomatic or rapidly enlarging tumors, ideally performed at centers with expertise in complex abdominal oncologic resections.

Long-term follow-up with cross-sectional imaging—typically contrast-enhanced MRI or CT—is recommended every 3–6 months during the first two years, then annually for at least five years. Patients should be counseled that recurrence is not inevitable but remains a substantial clinical concern requiring vigilant monitoring and individualized therapeutic planning.